Hematopoietic stem cell (HCT) transplantation offers curative therapy for a variety of malignant and nonmalignant disorders. It is limited by donor availability, transplant related toxicity, graft versus host disease, relapse of malignancy, infections, and for some patients, reduction in post-transplant quality of life. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) was established in 2001 to develop and execute scientifically meritorious, prospective clinical trials to address these issues. The Network has launched >20 trials with the support of a Data and Coordinating Center (DCC) comprised of a Consortium of the Center for International Blood and Marrow Transplant Research, the National Marrow Donor Program and The EMMES Corporation. The members of this DCC Consortium propose to continue supporting the Network and managing the efficient development, implementation and completion of high-quality Phase l-lll clinical trials for the Network, including concept evaluation and prioritization, protocol development with appropriate statistical designs, timely activation and accrual, monitoring for safety, compliance and data accuracy, and analyzing and disseminating results. The DCC Consortium will coordinate and support all BMT CTN activities maintaining a state-of-the-art database and systems for acquisition and storage of biologic specimens, ensuring data quality, laboratory compliance and adherence to regulatory requirements, managing contractual arrangements and fiscal activities, monitoring and improving center and overall Network performance and supporting all Network committees and activities with meeting planning and other logistical support. The Consortium will also help amplify and leverage Network resources through collaboration with other scientific bodies including National Cancer Institute-funded Cancer Cooperative Groups and the Stem Cell Therapeutic Outcomes Database to maximize successful completion of high quality and high priority clinical trials in HCT.
The proposed Data and Coordinating Center (DCC) will support all activities of the BMT CTN, using the extensive expertise of the investigators in clinical research and transplantation. We will take advantage of collaborations with other organizations and initiatives to maximize efficiency and trial participation. The goal is to complete high quality clinical trials that focus on the most important barriers to transplant success.
|Ghosh, Nilanjan; Karmali, Reem; Rocha, Vanderson et al. (2016) Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol 34:3141-9|
|Steering Committee Of The Blood And Marrow Transplant Clinical Trials Network (2016) The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 22:1747-57|
|Wood, William A; McGinn, Margaret K; Wilson, Doug et al. (2016) Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians. Biol Blood Marrow Transplant 22:2092-2099|
|Riches, M L; Trifilio, S; Chen, M et al. (2016) Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis. Bone Marrow Transplant 51:277-82|
|D'Souza, Anita; Huang, Jiaxing; Hari, Parameswaran (2016) New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 22:768-70|
|Strouse, Christopher; Richardson, Paul; Prentice, Grant et al. (2016) Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 22:1306-12|
|Fenske, Timothy S; Ahn, Kwang W; Graff, Tara M et al. (2016) Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol 174:235-48|
|Kanate, Abraham S; Mussetti, Alberto; Kharfan-Dabaja, Mohamed A et al. (2016) Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood 127:938-47|
|Teira, Pierre; Battiwalla, Minoo; Ramanathan, Muthalagu et al. (2016) Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood 127:2427-38|
|Klyuchnikov, E; Bacher, U; Woo Ahn, K et al. (2016) Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. Bone Marrow Transplant 51:58-66|
Showing the most recent 10 out of 143 publications